Want to see IMRX full AI Analyst Report?
IMRX Stock Chart & Stats
$5.15
$0.04(0.93%)
At close: 4:00 PM EDT
$5.15
$0.04(0.93%)
Day’s Range― - ―
52-Week Range$3.38 - $8.48
Previous Close$4.39
Volume459.78K
Average Volume (3M)728.37K
Market Cap
$241.32M
Enterprise Value$176.57M
Total Cash (Recent Filing)$149.90M
Total Debt (Recent Filing)$3.63M
Price to Earnings (P/E)―
Beta1.65
Next Earnings
Nov 05, 2026EPS Estimate
-0.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.04
Shares Outstanding64,697,400
10 Day Avg. Volume851,065
30 Day Avg. Volume728,373
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)1.33
Price to Sales (P/S)0.00
P/FCF Ratio-6.37
Enterprise Value/Market Cap0.73
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-222.61
Enterprise Value/Ebitda-2.86
Forecast
1Y Price Target
$14.00Price Target Upside171.84% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-1.12
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageVery low leverage gives Immuneering greater flexibility while it funds clinical development and absorbs operating losses. The substantial equity cushion reduces dependence on debt financing, limits interest burden, and provides a stronger balance-sheet base than many development-stage biotechnology companies.
Clinical Program ProgressProgression from Phase 2a toward a pivotal Phase 3 program can materially improve the company’s long-term opportunity if efficacy and safety remain supportive. The data and defined development path provide a clearer route toward potential clinical validation and future commercialization.
Computational Biology PlatformA computational biology platform focused on disease-related networks can support repeatable discovery across multiple oncology programs rather than relying on one isolated asset. Its application to MAPK and other cancer pathways may create a durable research engine if candidates continue advancing clinically.
Bears Say
Persistent Cash BurnPersistent operating cash outflows show that Immuneering currently requires substantial funding to sustain research and clinical development. Continued burn can reduce financial flexibility over time and may lead to future capital raises, dilution, or slower advancement of the pipeline.
Limited Revenue BaseThe absence of sustained revenue means Immuneering has no established commercial offset to its research costs and remains dependent on successful clinical execution. Until a program reaches meaningful commercialization, earnings visibility and internally generated funding capacity remain weak.
Deep Ongoing LossesLarge and persistent net losses reflect an R&D-heavy business that has not yet reached economic scale. If losses continue through later development stages, shareholder capital will keep being consumed, increasing the importance of clinical milestones and disciplined spending.
Immuneering News
IMRX FAQ
What was Immuneering’s price range in the past 12 months?
Immuneering lowest stock price was $3.38 and its highest was $8.48 in the past 12 months.
What is Immuneering’s market cap?
Immuneering’s market cap is $241.32M.
When is Immuneering’s upcoming earnings report date?
Immuneering’s upcoming earnings report date is Nov 05, 2026 which is in 15 days.
How were Immuneering’s earnings last quarter?
Immuneering released its earnings results on Aug 05, 2026. The company reported -$0.27 earnings per share for the quarter, missing the consensus estimate of -$0.269 by -$0.001.
Is Immuneering overvalued?
According to Wall Street analysts Immuneering’s price is currently Undervalued.
Does Immuneering pay dividends?
Immuneering does not currently pay dividends.
What is Immuneering’s EPS estimate?
Immuneering’s EPS estimate is -0.31.
How many shares outstanding does Immuneering have?
Immuneering has 64,697,400 shares outstanding.
What happened to Immuneering’s price movement after its last earnings report?
Immuneering reported an EPS of -$0.27 in its last earnings report, missing expectations of -$0.269. Following the earnings report the stock price went down -0.227%.
Which hedge fund is a major shareholder of Immuneering?
Currently, no hedge funds are holding shares in IMRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Immuneering Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$14.00 (171.84% Upside)
$14.00 (171.84% Upside)
Blogger Sentiment
Bullish
IMRX Sentiment 83%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Increased
By 88.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 2.6%
Last 30 Days ▼ 2.6%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-33.51%
12-Months-Change
Fundamentals
Return on Equity
-27.15%
Trailing 12-Months
Asset Growth
404.43%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Immuneering
Immuneering Corporation is a biopharmaceutical company dedicated to developing novel therapeutic candidates in the fields of oncology (cancer) and neuroscience. Leading its clinical development efforts are two key drug candidates: IMM-1-104, a dual-MEK inhibitor intended for the treatment of various cancers, including pancreatic, melanoma, colorectal, and non-small cell lung cancer, specifically those driven by RAS and/or RAF gene mutations. The second is IMM-6-415, which is being developed to treat solid tumors. Beyond these advanced-stage programs, Immuneering's early-stage pipeline includes five oncology initiatives aimed at components of the MAPK or mTOR signaling pathways, along with two neuroscience programs, all currently in the discovery phase. Founded in 2008, Immuneering Corporation is headquartered in Cambridge, Massachusetts. It was formerly a subsidiary of Teva Pharmaceutical Industries Limited.
IMRX Stock 12 Month Forecast
Average Price Target
$14.00
▲(171.84% Upside)
Technical Analysis
Ownership Overview
9.38% Insiders
15.57% Mutual Funds
0.50% Other Institutional Investors
65.45% Public Companies and
Individual Investors